Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025.
The FDA has announced that popular weight loss medication tirzepatide is no longer in shortage, potentially removing cheaper versions of the drug from the market by early 2025.
With the official shortage over, the FDA has signaled it will crack down on compounded tirzepatide, affecting patients who've relied on the lower-priced medication.
The cheaper option is sold in vials in an effort to sidestep supply-chain issues with the prefilled pens and compete with compounded drugs.
More brand-name GLP-1 drugs are on the horizonMore FDA news could continue to change the trajectory of GLP-1 drugs in the coming months.
Persons:
tirzepatide, Eli Lilly's, Ted Kyle, Eli Lilly, annoucement, Scott Brunner, Henry Meds, Ro, Kyle
Organizations:
FDA, semaglutide, Manufacturers, Alliance, Pharmacy